HUE063528T2 - Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére - Google Patents

Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére

Info

Publication number
HUE063528T2
HUE063528T2 HUE16763663A HUE16763663A HUE063528T2 HU E063528 T2 HUE063528 T2 HU E063528T2 HU E16763663 A HUE16763663 A HU E16763663A HU E16763663 A HUE16763663 A HU E16763663A HU E063528 T2 HUE063528 T2 HU E063528T2
Authority
HU
Hungary
Prior art keywords
antibodies
treatment
lupus nephritis
nephritis
lupus
Prior art date
Application number
HUE16763663A
Other languages
English (en)
Inventor
Scott Ronald Brodeur
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of HUE063528T2 publication Critical patent/HUE063528T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE16763663A 2015-09-01 2016-08-31 Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére HUE063528T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27

Publications (1)

Publication Number Publication Date
HUE063528T2 true HUE063528T2 (hu) 2024-01-28

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16763663A HUE063528T2 (hu) 2015-09-01 2016-08-31 Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére

Country Status (16)

Country Link
US (3) US20170058038A1 (hu)
EP (1) EP3344655B1 (hu)
JP (2) JP2018529661A (hu)
KR (1) KR20180039172A (hu)
CN (1) CN107922501A (hu)
AU (1) AU2016317028B2 (hu)
BR (1) BR112018001907A2 (hu)
CA (1) CA2993996A1 (hu)
CL (1) CL2018000317A1 (hu)
DK (1) DK3344655T3 (hu)
ES (1) ES2969968T3 (hu)
HU (1) HUE063528T2 (hu)
MX (1) MX2018002447A (hu)
PH (1) PH12018500445A1 (hu)
PL (1) PL3344655T3 (hu)
WO (1) WO2017040566A1 (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
BR112020024078A2 (pt) * 2018-06-29 2021-02-17 Boehringer Ingelheim International Gmbh anticorpos anti-cd40 para uso no tratamento de doença autoimune
CA3121291A1 (en) * 2018-11-30 2020-06-04 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
CN116963774A (zh) 2021-01-28 2023-10-27 瑞泽恩制药公司 用于治疗细胞因子释放综合征的组合物和方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE69315847T2 (de) 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
AU2005323515A1 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
PL1885399T3 (pl) * 2005-05-26 2011-04-29 Seattle Genetics Inc Humanizowane przeciwciała anty-CD40 i sposoby ich stosowania
EA018301B1 (ru) * 2006-04-21 2013-07-30 Новартис Аг Фармацевтические композиции, содержащие антагонистическое моноклональное антитело к cd40, и их применение
AR081750A1 (es) * 2010-03-31 2012-10-17 Boehringer Ingelheim Int Anticuerpos anti-cd40
RU2609647C2 (ru) * 2011-04-29 2017-02-02 Апексиджен, Инк. Анти-cd40-антитела и способы применения
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
US20230265203A1 (en) 2023-08-24
JP2021185169A (ja) 2021-12-09
PH12018500445A1 (en) 2018-09-10
MX2018002447A (es) 2018-06-15
WO2017040566A1 (en) 2017-03-09
CN107922501A (zh) 2018-04-17
PL3344655T3 (pl) 2024-02-19
US20190177420A1 (en) 2019-06-13
AU2016317028B2 (en) 2021-09-09
US20170058038A1 (en) 2017-03-02
EP3344655B1 (en) 2023-07-26
EP3344655A1 (en) 2018-07-11
ES2969968T3 (es) 2024-05-23
KR20180039172A (ko) 2018-04-17
DK3344655T3 (da) 2023-10-09
AU2016317028A1 (en) 2018-02-22
CL2018000317A1 (es) 2018-07-20
BR112018001907A2 (pt) 2018-09-25
CA2993996A1 (en) 2017-03-09
JP2018529661A (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
ZA201708448B (en) Anti-cd38 antibodies for treatment of acute lymphoblastic leukemia
HK1247221A1 (zh) 用於治療急性髓系白血病的抗cd38抗體
ZA201703585B (en) Combination immunotherapy approach for treatment of cancer
HK1247823A1 (zh) 骨質疏鬆的治療
DK3143025T3 (da) Forbindelser til behandling af spinal muskelatrofi
IL285077A (en) Compounds for the treatment of cancer
EP3137087A4 (en) Estrogen combination for treatment of multiple sclerosis
IL248697A0 (en) Methods for purifying antibodies
HK1258994A1 (zh) 用於疾病治療的方法
IL247954A0 (en) Immunoglobulin mobilisation
IL258593A (en) Compounds for the treatment of subculture disorders
PL3344655T3 (pl) Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek
EP3137089A4 (en) Use of ginsenoside m1 for treating lupus nephritis
IL246540A0 (en) Freezeald receptor antibodies for cancer treatment
ZA201907460B (en) Improved protocol for treatment of lupus nephritis
HK1246679A1 (zh) 絲蟲病的治療
IL269419A (en) Treatment of lupus using human anti-CZCR5 antibodies
ZA201704589B (en) Compounds for the treatment of cancer